Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/20/2025

Comparative Efficacy and Safety of Enalapril and Telmisartan

Introduction to Enalapril and Telmisartan

  • The European Society of Cardiology recommends considering the use of telmisartan as an alternative to ACE inhibitors like enalapril due to its superior tolerability and metabolic benefits 1

Comparative Efficacy in Cardiovascular Protection

  • Both enalapril and telmisartan effectively reduce morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), according to the American College of Cardiology 3
  • Telmisartan has demonstrated cardiovascular protective effects in high-risk patients comparable to ACE inhibitors like ramipril in large clinical trials such as ONTARGET, as reported by the American Heart Association 2

Tolerability and Side Effect Profile

  • ACE inhibitors like enalapril have a higher incidence of cough (up to 20% of patients) compared to ARBs, which is a significant consideration for patient adherence, as noted by the European Heart Journal 3
  • ARBs including telmisartan have a side effect profile comparable to placebo in many studies, making them better tolerated than ACE inhibitors, according to the European Society of Cardiology 1

Unique Properties of Telmisartan

  • Telmisartan has unique partial PPAR-gamma agonist activity, providing additional metabolic benefits not seen with ACE inhibitors like enalapril, as reported by the American Diabetes Association 2

Renal Protection

  • Telmisartan significantly reduces progression to overt nephropathy in patients with type 2 diabetes and albuminuria, with benefits persisting even after adjustment for blood pressure differences, according to the National Kidney Foundation 4

Clinical Indications

  • ARBs like telmisartan are recommended for patients who are intolerant to ACE inhibitors due to cough or angioedema, as suggested by the American College of Cardiology 3
  • Telmisartan is particularly effective for patients with left ventricular hypertrophy, according to the European Society of Cardiology 4

Safety Considerations

  • Both medications require monitoring of renal function and serum potassium levels, as recommended by the National Kidney Foundation 2, 4
  • Combination therapy with other renin-angiotensin system blockers should be avoided due to increased risk of adverse events, as warned by the American Heart Association 2, 4